Freddy A. Jimenez sold 4,166 shares of Celldex Therapeutics for $121,210, representing 11.92% of his direct holdings, reducing his stake to 30,796 shares. The sale was all in direct ownership, with no involvement of indirect entities or derivative securities.

Jimenez, Senior VP & General Counsel, executed the sale on Dec. 4, 2025, reported in a SEC Form 4 filing. The transaction value was $121,210, based on a price of $29.09 per share. His post-transaction direct ownership value was $895,856.

Comparing to his prior sale, Jimenez’s recent transaction was larger, affecting 11.92% of his total equity interest. He now holds 30,796 shares directly, with no indirect holdings as of Dec. 8, 2025.

Celldex Therapeutics, with a market cap of $1.82 billion, focuses on developing therapeutic antibodies targeting inflammatory diseases and oncology. The company operates in a research-driven biopharmaceutical model, collaborating on research and licensing agreements.

In addition to Jimenez’s sale, SVP & CBO Pepin Ronald acquired 19,333 shares, while SVP and CFO Martin Samuel Bates acquired 4,817 shares by exercising stock options. The company’s financials have been deteriorating, with zero revenue in Q3 FY2025 and worsening net losses.

Celldex Therapeutics SVPs have been engaging in heavy transactions recently. The company’s financials are declining, with no revenue in Q3 FY2025 and worsening net losses. Insider transactions by SVPs raise questions about the company’s future prospects.

Read more at Yahoo Finance: Celldex Therapeutics SVPs Engage In Heavy Transactions